Where Compassion Meets Cardiovascular Excellence

CTO-PCI in Hyderabad —
Chronic Total Occlusion Angioplasty

Home Services
Dr Bhishma Chowdary cardiologist in Hyderabad
Dr Bhishma Chowdary cardiologist in Hyderabad

chronic-total-occlusions

A chronic total occlusion (CTO) is one of the most challenging problems in interventional cardiology — a coronary artery that has been completely blocked for three months or more, often causing persistent chest pain, breathlessness, and reduced quality of life. CTO-PCI is a highly specialised procedure to reopen these blocked arteries, requiring advanced training, dedicated equipment, and meticulous case planning. Dr. Bhishma Chowdary performs CTO-PCI at AIG Hospitals, Gachibowli, Hyderabad — one of the few centres in the region offering this advanced intervention.

At a Glance

Procedure type Complex percutaneous coronary intervention (PCI) — specialised angioplasty
Condition treated Chronic total occlusion (CTO) — complete coronary artery blockage present for 3+ months
Duration 2 to 4 hours (varies with complexity)
Anaesthesia Local anaesthesia + conscious sedation. Awake throughout.
Access Dual arterial access — both wrists, or wrist + groin (required for retrograde techniques)
Hospital stay 48 to 72 hours
Success rate 85 to 95% in experienced hands (contemporary series)
Imaging guidance IVUS used routinely for stent optimisation
Planning scan CT angiography before procedure for complex cases
Performed by Dr. Bhishma Chowdary, DM Cardiology, AIG Hospitals Hyderabad
Appointment +91-9000352998

What is a chronic total occlusion?

A chronic total occlusion is defined as a coronary artery that is 100% blocked — with TIMI 0 flow (no blood passing through) — for a duration of three months or longer. Unlike a heart attack, where a sudden blockage cuts off blood supply in minutes, a CTO develops gradually over months or years as cholesterol plaque accumulates and eventually fills the vessel completely.

The blocked segment is not simply soft plaque. Over time it becomes a hard, organised structure of fibrous tissue, calcium deposits, and sometimes micro-channels — making it very different from ordinary coronary blockages and much harder to cross with standard angioplasty equipment.

CTOs are found in approximately 15 to 20% of all patients who undergo coronary angiography, making them far more common than many patients realise. They are often found incidentally during investigation for symptoms, or discovered when a prior angiogram is reviewed.

What happens to the heart muscle beyond a CTO?

The heart muscle supplied by the blocked artery does not necessarily die — it may survive in a state of chronic low activity called hibernation, drawing just enough blood through small collateral vessels from other arteries to stay alive but not enough to function normally. Successful CTO-PCI can wake up hibernating heart muscle, improving function weeks to months after the procedure.

Why treat a chronic total occlusion?

The question of whether a CTO should be opened is one that requires careful individual assessment. Not every CTO requires treatment — if it is causing no symptoms, the heart muscle beyond it is not viable, or the patient's overall risk profile makes intervention inadvisable, medical management alone may be appropriate.

However, when a CTO is causing significant symptoms or impacting heart function, successful CTO-PCI delivers documented benefits:

Symptom relief

  • Significant reduction in angina — chest pain, tightness, or pressure — that has not responded adequately to medications
  • Improved breathlessness on exertion as the heart muscle receives better blood supply
  • Reduced dependence on antianginal medications (nitrates, beta-blockers, calcium channel blockers)
  • Better exercise tolerance and overall quality of life

Heart function improvement

  • Recovery of hibernating heart muscle in the territory supplied by the CTO vessel
  • Improvement in left ventricular ejection fraction (heart pumping strength) — seen particularly in patients with reduced baseline function
  • Reduced risk of arrhythmias arising from ischaemic heart muscle

Prognostic benefit

  • Complete revascularisation — treating all significant blockages including CTOs — is associated with better long-term outcomes compared to leaving a CTO untreated alongside stenting other vessels
  • Providing a 'safety net': a successfully opened CTO vessel can supply blood to other heart territories if a different coronary artery becomes acutely blocked in future

When is medical management alone appropriate?

CTO-PCI is not indicated when the vessel is very small, the territory of heart muscle supplied is minimal, the heart muscle beyond the CTO is not viable (confirmed on imaging), or the patient's risk for the procedure outweighs the expected benefit. Dr. Bhishma Chowdary performs a thorough clinical and imaging assessment before recommending CTO-PCI to ensure the procedure is genuinely in the patient's best interest.

Assessing heart muscle viability before CTO-PCI

Before proceeding with CTO-PCI, it is important to confirm that the heart muscle supplied by the blocked artery is still alive and capable of recovery — not permanently scarred from a prior heart attack. Treating a CTO supplying irreversibly damaged muscle provides little benefit.

Viability can be assessed using:

Stress echocardiography Assesses wall motion during stress. Segments that are hibernating (alive but dormant) show reduced function at rest but may demonstrate contractile reserve. More accessible and widely available.
Cardiac MRI (CMR) The gold standard for viability assessment. Gadolinium late enhancement imaging identifies areas of irreversible scar versus viable hibernating muscle with high precision. Available at AIG Hospitals.
Nuclear myocardial perfusion scan (MPS / SPECT) Demonstrates perfusion and metabolic activity of heart muscle. Viable muscle retains tracer uptake. Historically the most used viability modality.
CT angiography Also used for procedural planning — maps the CTO morphology, length, calcium burden, and distal vessel anatomy before the procedure.

CTO complexity scoring — the J-CTO and PROGRESS CTO scores

Not all CTOs are equally difficult to treat. A number of validated scoring systems help cardiologists predict procedural difficulty and plan the most appropriate crossing strategy before the patient enters the cath lab.

J-CTO score Predicts procedural success based on: right coronary artery CTO, cap ambiguity, absence of interventional collaterals, and moderate/severe tortuosity. Used alongside J-CTO in contemporary practice.
PROGRESS CTO Score Predicts procedural success based on: right coronary artery CTO, proximal cap ambiguity, absence of interventional collaterals, and moderate/severe tortuosity. Used alongside J-CTO in contemporary practice.
CASTLE Score Predicts in-hospital major adverse cardiac events (MACE) — helping identify patients who need extra preparation such as mechanical circulatory support (Impella) prophylactically for the procedure.

What this means for you

Before your CTO-PCI, Dr. Bhishma Chowdary reviews your angiogram and CT images carefully, calculates complexity scores, and presents a detailed procedural plan including the anticipated crossing strategy, estimated success probability, and safety preparations. You will know exactly what to expect before the procedure begins.

CTO-PCI crossing techniques — what makes it different

Standard angioplasty navigates a guidewire through a narrowed but still-open artery — the wire simply follows the existing channel. In CTO-PCI, the wire must penetrate and traverse a completely blocked, often calcified and fibrous segment. This requires a suite of specialised techniques:

1. Antegrade wiring — approaching from the front

The most straightforward approach. A specialised CTO guidewire — stiffer and more tapered than standard wires — is advanced from the proximal end of the blockage and navigated through the occlusion towards the distal vessel. Various wire escalation strategies are used, beginning with softer wires and progressing to harder, more penetrating wires if needed.

  • Antegrade wire escalation: Progressive use of wires with increasing tip load and hardness
  • Antegrade dissection re-entry (ADR): Deliberately entering the space between the artery wall layers (subintimal space) and then re-entering the true vessel lumen beyond the blockage using re-entry devices such as the Stingray balloon and wire system

2. Retrograde approach — crossing from behind

When antegrade techniques fail or are anatomically unsuitable, the CTO can be approached from the other end — retrograde. A guidewire is passed backwards through collateral channels (small natural connecting vessels between coronary arteries) that have developed around the blockage, reaching the distal end of the CTO from behind.

  • Septal collateral crossing: Using collateral channels running through the interventricular septum — the preferred retrograde route due to lower risk
  • Epicardial collateral crossing: Using surface collaterals on the outer heart wall — used when septal collaterals are absent or unsuitable
  • Retrograde dissection re-entry (RDR / CART / reverse CART): After crossing retrogradely, the wire is manoeuvred to meet the antegrade wire and allow externalization — pulling the retrograde wire out through the guide catheter to establish a continuous rail for balloon and stent delivery

3. Hybrid CTO approach

The contemporary standard for CTO-PCI is the hybrid algorithm — a systematic, pre-planned decision framework that selects the best crossing strategy based on specific anatomical features of each CTO. Rather than committing to a single technique, the operator moves fluidly between antegrade and retrograde approaches based on real-time findings. Dr. Bhishma Chowdary follows the hybrid algorithm for all CTO cases, ensuring the most efficient path to success with the lowest risk of complications.

Specialised equipment used in CTO-PCI

CTO-PCI requires equipment not used in routine angioplasty:

CTO guidewires Tapered tip wires with varying stiffness and penetrating capacity. Examples: Fielder XT, Miracle series, Confianza Pro, Hornet — each suited to different CTO morphologies.
Microcatheters Thin support catheters that track over guidewires, improving wire transmission of force and allowing wire exchanges deep within complex anatomy. Essential for CTO crossing.
Stingray balloon and wire A flat balloon that appositions against the artery wall, with a dedicated wire that re-enters the true lumen from the subintimal space. The standard tool for antegrade dissection re-entry.
Knuckle wire technique Deliberately forming a small loop (knuckle) on a polymer-jacketed wire to traverse the subintimal space safely without perforation.
Dual guide catheters Two arterial access sites are used simultaneously — one for the antegrade approach, one for retrograde. Requires meticulous coordination.
IVUS (intravascular ultrasound) Used after successful crossing and before stenting to confirm wire position in the true lumen, measure vessel dimensions accurately, and optimise stent deployment — critical in CTO cases where vessel calibre is often uncertain.
Impella / IABP Mechanical circulatory support used prophylactically in patients with reduced heart function or complex multi-vessel CTO-PCI to protect against haemodynamic compromise during the procedure.

What to expect — step by step

Pre-procedure (1 to 2 weeks before)

  • CT angiography of the CTO and access vessels is reviewed for procedural planning.
  • Viability assessment (stress echo or cardiac MRI) if heart function is reduced.
  • Complexity scoring and strategy planning — the team agrees on primary and backup crossing approaches.
  • Optimisation of antiplatelet therapy: Dual antiplatelet therapy (aspirin + ticagrelor or clopidogrel) is ideally established for at least 5 to 7 days before elective CTO-PCI.
  • Renal function and hydration optimised — CTO-PCI uses more contrast dye than routine angioplasty.

On the day

  1. Admission and preparation. IV access, ECG monitoring, blood tests.
  2. Dual arterial access is established — typically both wrists (bilateral radial), or right wrist and right groin. Both sites are numbed with local anaesthetic.
  3. Two guide catheters are positioned — one at the proximal end of the CTO vessel, one for retrograde access if needed.
  4. Heparin anticoagulation is given. Activated clotting time (ACT) is monitored throughout.
  5. Crossing is attempted using the planned strategy. The team communicates clearly — you remain comfortable throughout with sedation available as needed.
  6. Once crossing is achieved, IVUS imaging is performed to confirm true lumen position and measure the vessel before stenting.
  7. The blocked segment is predilated with balloons and stented. Drug-eluting stents are used throughout. IVUS confirms optimal stent expansion and apposition after deployment.
  8. Final angiography confirms restored blood flow (TIMI 3 flow) through the entire previously blocked vessel.
  9. Access sites are closed. Wrist compression bands are applied.
  10. You are transferred to the ward for monitoring.

After the procedure

  • Monitored on the cardiac ward for 48 to 72 hours.
  • ECG monitoring for arrhythmias and any signs of haemodynamic change.
  • Renal function checked the following morning — contrast dye use is higher in CTO procedures.
  • Dr. Bhishma Chowdary reviews the procedural result with you and your family before discharge.
  • Dual antiplatelet therapy (aspirin + ticagrelor or clopidogrel) continued for at least 12 months.
  • Follow-up appointment at 4 to 6 weeks with clinical review and ECG.

What happens if the CTO cannot be opened?

Despite the best techniques and most experienced operators, some CTOs cannot be successfully crossed — particularly the most complex cases with heavily calcified, tortuous, or ambiguous anatomy. Contemporary success rates in high-volume CTO centres are 85 to 95%, meaning a small proportion of cases remain unsuccessful even in expert hands.

If a CTO cannot be opened in a single attempt, this does not mean the situation is hopeless. Options include:

  • Medical therapy optimisation — ensuring maximum antianginal medication is in place to control symptoms.
  • Repeat CTO-PCI attempt — often with a modified strategy, additional planning, or after further imaging. A second attempt by an experienced operator succeeds in many cases where a first attempt did not.
  • Surgical referral — bypass surgery can successfully revascularise CTO territory that is not amenable to catheter-based intervention.
  • Hybrid cardiology-surgery discussion — complex cases are reviewed jointly at AIG Hospitals to determine the most appropriate path.

Important reassurance

An unsuccessful CTO-PCI attempt does not make the clinical situation worse in the vast majority of cases. The decision to attempt CTO-PCI is made only when the expected benefit outweighs procedural risk — and a failed attempt simply returns the patient to the pre-procedure state. Dr. Bhishma Chowdary will only recommend CTO-PCI when it is genuinely in your best interest, and will be fully transparent about expected success probability before proceeding.

Frequently asked questions

How is CTO-PCI different from regular angioplasty?

In regular angioplasty, the artery is narrowed but still open — a standard guidewire can be advanced through the existing channel relatively straightforwardly. In CTO-PCI, the artery is completely blocked with hard fibrous and calcified tissue that has been present for months or years. Specialised CTO wires, microcatheters, and advanced crossing techniques (including retrograde approaches through collateral vessels) are required. CTO-PCI typically takes 2 to 4 hours compared to 30 to 90 minutes for routine angioplasty, and requires specific training and high-volume experience to perform safely and effectively.

I was told my CTO cannot be opened. Can Dr. Bhishma Chowdary reassess this?

Yes. A significant number of patients referred for CTO-PCI have previously been told the blockage is untreatable or that the risk is too high. Advances in CTO technique — particularly retrograde crossing and the hybrid algorithm — have dramatically expanded what is technically possible. An up-to-date angiogram review and CT planning often reveals crossing strategies that were not available when the original assessment was made. Dr. Bhishma Chowdary is happy to review your angiogram and provide an independent assessment of CTO-PCI feasibility.

Will I be put under general anaesthesia for CTO-PCI?

No. CTO-PCI is performed under local anaesthesia at the access sites with conscious sedation — you remain awake and comfortable throughout. General anaesthesia is not required. The procedure is longer than routine angioplasty, so sedation is titrated carefully to keep you relaxed and comfortable for the duration. You will be able to communicate with the team at all times.

How much radiation exposure is involved in CTO-PCI?

CTO-PCI uses more X-ray fluoroscopy time than routine angioplasty due to the complexity and duration of the procedure. Dr. Bhishma Chowdary uses modern cath lab equipment with optimised low-dose protocols and employs strict radiation reduction techniques — including limiting fluoroscopy time, using last-image hold, and careful collimation. The dose is monitored throughout and remains within safe clinical limits. Cumulative radiation effects from a single CTO procedure are not a significant clinical concern.

How much contrast dye is used? Is it safe for my kidneys?

CTO-PCI typically uses more contrast dye than routine angioplasty. For patients with pre-existing kidney disease, careful preparation is essential. Dr. Bhishma Chowdary reviews kidney function before every CTO case. Preventive measures include adequate hydration in the 24 hours before the procedure, limiting contrast volume through judicious use, and avoiding other nephrotoxic medications around the time of the procedure. Most patients with mild to moderate kidney impairment can safely undergo CTO-PCI with these precautions.

My doctor told me I have collaterals supplying the CTO territory. Does that mean I don't need the procedure?

Collateral vessels are small natural bypass channels that develop around a CTO to maintain some blood supply to the affected territory. While collaterals prevent the muscle from dying, they rarely provide enough blood flow for the muscle to function normally — especially during exertion. Patients with collaterals still commonly experience angina and reduced exercise tolerance. Successful CTO-PCI restores full, direct blood flow — replacing the limited collateral supply with normal arterial flow — and typically leads to significant symptom improvement even when collaterals were present.

How long before I notice improvement in my symptoms after CTO-PCI?

Many patients notice improvement in breathlessness and chest pain within the first 2 to 4 weeks after a successful CTO-PCI. However, hibernating heart muscle — which has been underperfused for months or years — takes time to recover function after revascularisation. The maximum benefit in heart muscle recovery is typically seen at 3 to 6 months after the procedure. Patients with significantly reduced heart function before CTO-PCI may see progressive improvement in ejection fraction over this period.

Is CTO-PCI suitable for elderly patients?

Age alone is not a contraindication to CTO-PCI. Elderly patients with good functional status and viable heart muscle can benefit substantially from CTO-PCI with improvement in angina and quality of life. The procedural risk assessment takes into account the patient's overall health, kidney function, and cardiac status — not age in isolation. Dr. Bhishma Chowdary has experience performing CTO-PCI in elderly patients including those requiring mechanical circulatory support.

What is the risk of heart attack during CTO-PCI?

The risk of a significant periprocedural myocardial infarction (heart attack) during CTO-PCI is approximately 1 to 3% in contemporary series — somewhat higher than routine angioplasty, reflecting the procedure's complexity. Coronary perforation (a small tear in the artery wall) occurs in approximately 1 to 2% of cases and is usually manageable with balloon tamponade or a covered stent. These risks are carefully weighed against the expected benefit for each patient before recommending the procedure. Meticulous planning, experienced operators, and full backup facilities — including cardiac surgery on site at AIG Hospitals — are essential safety requirements for CTO-PCI.

CTO-PCI versus bypass surgery — how is the choice made?

For patients with a CTO, both catheter-based CTO-PCI and surgical bypass (CABG) can achieve revascularisation of the blocked territory. The choice depends on:

Number of diseased vessels Isolated CTO with no other significant disease — CTO-PCI preferred if technically feasible. CTO with triple vessel disease — bypass surgery may offer more complete revascularisation.
CTO anatomy Favourable anatomy (short, not heavily calcified, clear cap) — CTO-PCI first choice. Very complex anatomy (J-CTO score 3–4) — surgery may be preferred, especially if other bypass indication exists.
Prior bypass surgery Patients with prior CABG may have degenerated or occluded grafts — CTO-PCI of the native vessel may be preferred over redo bypass.
Patient fitness for surgery High surgical risk due to frailty, lung disease, or prior sternotomy — CTO-PCI is strongly favoured.
Patient preference Avoiding major surgery and preferring a catheter-based approach, after informed discussion, is a valid consideration in the decision.

Heart Team approach at AIG Hospitals

Complex CTO cases are discussed at the AIG Hospitals multidisciplinary Heart Team meeting — including interventional cardiology and cardiac surgery — before a recommendation is made. This ensures each patient receives the most appropriate revascularisation strategy for their anatomy, risk profile, and preferences.

Why choose Dr. Bhishma Chowdary for CTO-PCI in Hyderabad?

  • DM Cardiology from Amrita Institute of Medical Sciences, Kochi — with dedicated interventional training including complex coronary intervention.
  • Proficiency in both antegrade and retrograde CTO crossing techniques including the hybrid CTO algorithm.
  • Routine IVUS guidance for CTO stenting — ensuring optimal stent sizing, expansion, and long-term outcomes.
  • Experience with complex calcific CTO-PCI — presented at the Complex PCI conference (national CTO-focused meeting).
  • Mechanical circulatory support (Impella, IABP) available on-site for high-risk CTO cases with reduced heart function.
  • Cardiac CT and cardiac MRI viability assessment available at AIG Hospitals for complete pre-procedure workup.
  • Cardiac surgery backup on-site — an essential safety requirement for CTO-PCI that is not available at all centres.
  • Transparent pre-procedure counselling — realistic success probability, risk discussion, and alternative options always presented.
  • Fluent consultations in English, Hindi, and Telugu.

Book a CTO-PCI consultation in Hyderabad

If you have been told you have a chronic total occlusion, have persistent chest pain or breathlessness despite medications, or have been advised that your CTO cannot be treated — contact Dr. Bhishma Chowdary at AIG Hospitals for an expert assessment and a second opinion on CTO-PCI feasibility.

Call: +91-9000352998

Email: bhishmachowdary@gmail.com

Location: AIG Hospitals, Gachibowli, Hyderabad — 500032

Clinic hours: Monday to Saturday, 10:00 AM to 4:00 PM

Related services